These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25617176)

  • 41. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism.
    Nappi C; Farace MJ; Leone F; Minutolo M; Tommaselli AP; Montemagno U
    Eur J Obstet Gynecol Reprod Biol; 1987 Jul; 25(3):209-19. PubMed ID: 2956138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myasthenia gravis accompanied by premature ovarian failure and aggravation by estrogen.
    Li Y; Xiao B; Xiao L; Zhang N; Yang H
    Intern Med; 2010; 49(6):611-3. PubMed ID: 20228602
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Update on primary ovarian insufficiency.
    Hewlett M; Mahalingaiah S
    Curr Opin Endocrinol Diabetes Obes; 2015 Dec; 22(6):483-9. PubMed ID: 26512773
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Symptoms, health behavior and understanding of menopause therapy in women with premature menopause.
    Gibson-Helm M; Teede H; Vincent A
    Climacteric; 2014 Dec; 17(6):666-73. PubMed ID: 24742007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of body composition in POF and its association with bone mineral density and sex steroid levels.
    Luo X; Cheng R; Zhang J; Ma Y; Zhang J; Luo Y; Xu L
    Gynecol Endocrinol; 2018 Dec; 34(12):1027-1030. PubMed ID: 29883221
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bone mineral density in women with cytotoxic-induced ovarian failure.
    Howell SJ; Berger G; Adams JE; Shalet SM
    Clin Endocrinol (Oxf); 1998 Sep; 49(3):397-402. PubMed ID: 9861333
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fertility desires, choice of hormone replacement and the effect of length of time since menopause on bone density in women with premature ovarian insufficiency: a review of 223 consecutive new referrals to a tertiary centre.
    Mittal M; Kreatsa M; Narvekar N; Savvas M; Hamoda H
    Post Reprod Health; 2014 Sep; 20(3):104-11. PubMed ID: 24973049
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mortality in COVID-19 among women on hormone replacement therapy: a retrospective cohort study.
    Dambha-Miller H; Hinton W; Wilcox CR; Joy M; Feher M; de Lusignan S
    Fam Pract; 2022 Nov; 39(6):1049-1055. PubMed ID: 35577349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of hormone replacement therapy on spinal bone mineral density and T lymphocyte subsets in premature ovarian failure and Turner's syndrome.
    Kurabayashi T; Yasuda M; Fujimaki T; Yamamoto Y; Oda K; Tanaka K
    Int J Gynaecol Obstet; 1993 Jul; 42(1):25-31. PubMed ID: 8103471
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ovarian benign clear cell adenofibroma in a patient with premature ovarian failure after 8-year hormone replacement therapy.
    Chen R; Zhou H; Zhang Y
    Gynecol Endocrinol; 2013 Mar; 29(3):216-8. PubMed ID: 23153077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of hormonal status on substrate utilization at rest and during exercise in the female population.
    Isacco L; Duché P; Boisseau N
    Sports Med; 2012 Apr; 42(4):327-42. PubMed ID: 22380007
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Study on risk factors of cardiovascular disease and the status of bone mineral density in women with hypoestrogenism].
    Zhao F; Guo XT; Cheng Y; Yang ZF; Liu HP
    Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):734-9. PubMed ID: 24406128
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sex steroids and breast cancer prevention.
    Spicer DV; Pike MC
    J Natl Cancer Inst Monogr; 1994; (16):139-47. PubMed ID: 7999456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy.
    Kalantaridou SN; Naka KK; Papanikolaou E; Kazakos N; Kravariti M; Calis KA; Paraskevaidis EA; Sideris DA; Tsatsoulis A; Chrousos GP; Michalis LK
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3907-13. PubMed ID: 15292326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Premature ovarian insufficiency - novel hormonal approaches in optimizing fertility.
    Dragojević Dikić S; Vasiljević M; Jovanović A; Dikić S; Jurišić A; Srbinović L; Vujović S
    Gynecol Endocrinol; 2020 Feb; 36(2):162-165. PubMed ID: 31311350
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Premature ovarian failure].
    van Kasteren YM
    Ned Tijdschr Geneeskd; 2000 Nov; 144(45):2142-6. PubMed ID: 11086487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Minimising menopausal side effects whilst treating endometriosis and fibroids.
    Simpson PD; McLaren JS; Rymer J; Morris EP
    Post Reprod Health; 2015 Mar; 21(1):16-23. PubMed ID: 25802141
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Premature climacteric as a special form of secondary ovarian insufficiency].
    Keck C; Breckwoldt M
    Ther Umsch; 2002 Apr; 59(4):193-8. PubMed ID: 12018038
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Premature ovarian insufficiency].
    Vogt EC; Russell HNB; Øksnes M; Lund A
    Tidsskr Nor Laegeforen; 2022 Aug; 142(11):. PubMed ID: 35997198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.